Welcome to our dedicated page for Xilio Therapeutics SEC filings (Ticker: XLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xilio Therapeutics, Inc. (Nasdaq: XLO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Xilio is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies, and its filings offer detailed information on clinical progress, collaborations, financings, governance and listing status.
Through this page, readers can review current reports on Form 8-K in which Xilio reports material events such as pipeline and business updates, clinical trial milestones, collaboration developments with partners like Gilead, Roche and AbbVie, financings and warrant exercises, cash runway estimates, Nasdaq listing matters and changes in board leadership. Filings also describe events such as the initiation of Phase 2 dosing for efarindodekin alfa (XTX301), late-breaking data for vilastobart in microsatellite stable metastatic colorectal cancer, and approvals of equity incentive plans and stock option repricings by stockholders.
Investors can also consult proxy statements on Schedule 14A to understand proposals submitted to stockholders, including equity plan approvals and adjournment proposals, as well as the mechanics of special meetings. Other periodic reports, such as Forms 10-Q and 10-K when available, provide additional context on research and development expenses, collaboration and license revenue, net loss and risk factors related to Xilio’s clinical-stage operations and Nasdaq listing compliance.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as updated financial guidance, listing notifications, and the implications of collaboration terms or option milestones. Users can quickly identify disclosures on topics like cash and cash equivalents, stockholders’ equity, minimum bid price grace periods, and the structure of development and commercialization options under Xilio’s license agreements. This makes it easier to interpret lengthy SEC documents and understand how Xilio’s masked immuno-oncology strategy is reflected in its regulatory reporting.
Xilio Therapeutics, Inc. reports that Nasdaq has notified the company it no longer meets the Nasdaq Global Select Market requirement to maintain at least $10.0 million in stockholders’ equity, after reporting stockholders’ equity of $7,069,000 in its Form 10-Q for the quarter ended June 30, 2025. The notice does not immediately affect trading of Xilio’s common stock. Xilio has 45 days, until October 6, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to 180 additional days to show it meets the equity standard or allow a transfer to the Nasdaq Capital Market if that market’s listing criteria are satisfied.
The company also reminds investors that it previously received a Nasdaq notice on April 4, 2025 for failing to maintain the $1.00 minimum bid price, with an initial 180‑day cure period expiring on October 1, 2025, and that it remains out of compliance with this bid price requirement. Xilio states that it is evaluating options to regain compliance with Nasdaq listing rules.
Gilead Sciences, Inc. reports beneficial ownership of 10,613,944 shares of Xilio Therapeutics, representing 19.9% of the outstanding common stock based on 51,827,910 shares outstanding. The filing states Gilead has sole voting and dispositive power over these shares. The holdings consist of 6,860,223 shares issued March 28, 2024; 485,250 shares issued April 3, 2024; 1,759,978 shares issued December 18, 2024; and 1,508,493 shares issuable upon exercise of pre-funded warrants. The statement certifies the shares were not acquired to change or influence control of the issuer.
Frazier-affiliated investment vehicles reported ownership of pre-funded warrants exercisable into Xilio Therapeutics (XLO) common stock. Several Frazier funds each directly hold warrants to acquire specific share amounts: Frazier Life Sciences Public Fund (reported cover-page amount 8,141,017 shares), Frazier Life Sciences Public Overage Fund (2,401,633), Frazier Life Sciences X (336,042), Frazier Life Sciences XI (894,779) and Frazier Life Sciences XII (1,561,529). Collectively these positions amount to 13,335,000 shares issuable upon exercise of the reported warrants (sum of the reported quantities). The filing explains that the percentages are calculated using 51,782,273 shares outstanding (as reported by the issuer), and notes that FLSPF’s exercisability is subject to a 9.99% beneficial ownership limitation (the cover pages show FLSPF at 9.9% due to rounding). The statement also corrects prior attributions and clarifies which committee members are not attributed beneficial ownership; certain individuals (e.g., James Topper and Patrick Heron) are reported as sharing voting and dispositive power over 336,042 shares held through FLS X.
Xilio Therapeutics (XLO) reported a mixed quarter with strengthened liquidity but continued operating losses that raise going concern questions. The company held $121.6 million of cash and cash equivalents and $1.8 million of restricted cash at June 30, 2025 (total $123.3 million including restricted cash). Xilio recognized $11.0 million of collaboration and license revenue in the six months ended June 30, 2025 and recorded $70.9 million of total deferred revenue related to agreements with Gilead and AbbVie.
Operating results show a $29.1 million net loss for the six months ended June 30, 2025 and an $412.9 million accumulated deficit. Management discloses that these losses and cash needs create substantial doubt about the company’s ability to continue as a going concern within twelve months. The company closed a June 2025 follow-on offering that produced $50.0 million of initial gross proceeds and issued prefunded warrants and detachable common stock warrants that could yield up to $100.0 million more if exercised. Xilio is also eligible for material contingent payments under collaborations: up to $2.1 billion from AbbVie and $592.5 million from Gilead, subject to achievement of milestones.
Xilio Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended June 30, 2025 and related business highlights. The company did this through a press release dated August 14, 2025, which is attached as Exhibit 99.1.
The press release and related information are furnished, not filed, meaning they are not subject to certain Exchange Act liabilities and are only incorporated into other filings if specifically referenced.